GSK's long-acting injection beats Truvada in HIV prevention trial

GlaxoSmithKline said cabotegravir was 69% more effective at preventing HIV infection for gay and bisexual men than pre-exposure prophylaxis (PrEP) pill Truvada

(Reuters) - GlaxoSmithKline (GSK.L) said on Monday an injection every other month of its antiviral drug cabotegravir was shown to be more effective at preventing an HIV infection than taking Gilead’s (GILD.O) Truvada pill every day.

The British drugmaker said the drug trial involving men who have sex with men was stopped early after cabotegravir was found to be 69% more effective than the current standard of care, Truvada.